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exists in terms of laboratory monitoring protocols and perceived
barriers regarding the use of these drugs.
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OBJECTIVES: To provide a review of the decision analytic
models used in the economic evaluations of Tumor Necrosis
Factor (TNF) inhibitors (adalimumab, etanercept, and inﬂix-
imab) in Rheumatoid Arthritis (RA) and to address some impor-
tant issues surrounding the choice of such analytic modeling
techniques in these economic analyses. METHODS: A system-
atic literature search was conducted by one researcher among
publications in peer-reviewed journals from January, 1996 to
October, 2004 through MEDLINE and EMBASE databases to
identify studies that used decision analysis models to evaluate
cost-effectiveness of TNF inhibitors in patients with RA. All the
studies of TNF inhibitors in patients other than RA, and those
conducted in children were excluded from the review. RESULTS:
The systematic literature search identiﬁed 28 articles. Of these
only ten studies fulﬁlled the inclusion criteria and were included
in the review process. These ten studies used different decision
analysis models, which are listed as follows: decision trees (two
studies), Markov model (four studies), Monte Carlo Simulation
(two studies), and Discrete Event Simulation (two studies). 
Since the models vary in complexity, the choice of these model-
ing techniques depends on the course of the disease, impact of
the drugs, and the availability of data. The results of most of the
studies indicate that all three TNF inhibitors are cost-effective
compared with traditional agents and have cost-effectiveness
ratios of less than $50,000/QALY gained. However, one study
reports the cost-effectiveness ratio of more than $100,000/QALY
for etanercept and inﬂiximab. CONCLUSION: Based on the
results derived from different modeling techniques, it would
seem that all methods provide useful techniques for economic
evaluations of TNF inhibitors. However, to increase the conﬁ-
dence of the physicians and payers, key issues such as validity of
the models, transparency during construction of the models,
quality of data sources, and handling of uncertainty need to be
resolved.
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OBJECTIVES: In patients with long-standing, severe RA who
failed methotrexate (MTX), we sought to determine whether
monotherapy with the fully human, anti-TNF monoclonal anti-
body, adalimumab, improved two important patient-reported
outcomes (health utility and fatigue) vs. placebo. METHODS:
The Health Utilities Index Mark 3 (HUI3) and the Functional
Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) ques-
tionnaire were administered in a health economics companion
study to a placebo-controlled, pivotal trial (DE011) of adali-
mumab monotherapy. HUI3 and FACIT-F were administered 
at baseline, three-months, and end of study. The HUI3 scale is
0–1, with “1” denoting perfect health and “0” denoting death.
FACIT-F scores range from 0–52, with higher scores represent-
ing less fatigue. Changes in HUI3 of >=0.03 and FACIT-F of >=4
are considered clinically meaningful. RESULTS: Patients received
either adalimumab 40mg every other week without concomitant
disease-modifying antirheumatic (DMARD) therapies (n = 99) or
placebo (n = 96) over 26-weeks. Baseline characteristics were
indicative of long-standing, severe RA: age: 53yrs; disease dura-
tion: 11yrs; TJC (0–68): 34; HAQ: 1.9, CRP (mg/L): 56.6; pre-
vious DMARDs: four (mean values). Baseline utility scores were
comparable for adalimumab and placebo (0.27 vs. 0.28), and
much worse than that of the age- and sex-adjusted population
norm (0.88). Similarly, baseline FACIT-F scores were also com-
parable (26.1 for adalimumab and 26.3 for placebo) and, again,
considerably worse than that of the general population (43.6).
After 26-weeks, mean HUI3 scores increased 0.18 from baseline
for adalimumab vs. 0.08 for placebo (p < 0.05). Mean FACIT-F
scores increased 8.7 for adalimumab vs. 3.3 for placebo (p <
0.01). CONCLUSION: Although optimal use of tumor necrosis
factor antagonists is with MTX, some patients do not tolerate
or beneﬁt from MTX. Adalimumab monotherapy provided 
statistically signiﬁcant, clinically meaningful improvements in
health utility and fatigue for patients with severe, long-standing
RA who had failed MTX therapy.
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OBJECTIVES: Patient satisfaction with medication is increas-
ingly set as treatment goal because it is hypothesized to increase
compliance. This study investigates plausible associations be-
tween levels of satisfaction with pain medication and external
variables (e.g., satisfaction with medication information, med-
ication characteristics, treatment efﬁcacy as perceived by the
patient) as established in the literature; to explore the effect of
satisfaction with pain medication on intention to comply with
current medication. METHODS: Rheumatoid arthritis (RA)
patients undergoing treatment were mailed two sets of ques-
tionnaires two-weeks apart: The Pain Treatment Satisfaction
Scale, the SF-36, a pain visual analogue scale, and the Brief Pain
Inventory. The inﬂuence of these variables on satisfaction with
pain medication was estimated using structural equation model-
ing. RESULTS: The population consisted of 68 RA patients with
a mean baseline pain score on a one to ten scale of 4.73 ± 2.72.
The overall model was signiﬁcant (chi-square p-value <0.001)
with an excellent ﬁt (normed ﬁt index = 0.97). The strongest
observed relationship was a positive association between satis-
faction with pain medication and intention to take pain med-
ication (unstandardized path coefﬁcient Beta = 0.54, p < 0.001).
Predictors of satisfaction with pain medication included duration
of pain relief (Beta = 0.45, p < 0.001), satisfaction with the infor-
mation provided by health care professionals (Beta = 0.21, p <
0.01) and expectations of pain relief (Beta = 0.20, p < 0.01).
CONCLUSION: RA patients’ intention to comply with pain
medication is inﬂuenced to a large extent by the level of satis-
faction with their pain medication. Duration of pain relief posi-
tively inﬂuences satisfaction with pain medication, as do (to a
lesser degree) satisfaction with information about treatment and
medication expectations. Improving compliance with care not
